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ABSTRACT
OBJECTIVE
To evaluate efficacies of anthelmintic drugs against 
soil transmitted helminths in terms of cure rates and 
egg reduction rates.
DESIGN
Systematic review and network meta-analysis.
DATA SOURCES
PubMed, ISI Web of Science, Embase, ScienceDirect, 
the Cochrane Central Register of Clinical Trials, and the 
World Health Organization library database from 1960 
until 31 December 2016.
STUDY SELECTION
Randomised controlled trials evaluating the efficacy of 
a single dose regimen of albendazole, mebendazole, 
levamisole, and pyrantel pamoate against Ascaris 
lumbricoides, hookworm (Necator americanus and 
Ancylostoma duodenale) and Trichuris trichiura. The 
primary outcomes included cure rates analysed by 
network meta-analysis with mixed logistic regression 
models and egg reduction rates with mixed linear 
models.
RESULTS
55 and 46 randomised controlled trials were included 
in the analysis of cure rates and egg reduction rates, 
respectively. All drugs were highly efficacious against 
A lumbricoides. Albendazole showed the highest 
efficacy against hookworm infections with a cure rate 
of 79.5% (95% confidence interval 71.5% to 85.6%) 
and an egg reduction rate of 89.6% (81.9% to 97.3%). 
All drugs had low efficacy against T trichiura, with 
mebendazole showing the highest cure rate of 42.1% 
(25.9% to 60.2%) and egg reduction rate of 66.0% 
(54.6% to 77.3%). Estimates for the years 1995 
and 2015 showed significant reductions in efficacy 
of albendazole against T trichiura: by 2015 the egg 
reduction rates fell from 72.6% (53.7% to 91.5%) to 
43.4% (23.5% to 63.3%; P=0.049) and the cure rates 
fell from 38.6% (26.2% to 52.7%) to 16.4 (7.7% to 
31.3%; P=0.027).
CONCLUSIONS
All four currently recommended drugs show 
limitations in their efficacy profile. While only 
albendazole showed good efficacy against hookworm 
infection, all drugs had low efficacy against T trichiura. 
The decrease in efficacy of albendazole against T 
trichiura over the past two decades is of concern. The 
findings indicate the need for strengthening efforts to 
develop new drug treatments, with a particular focus 
on drugs against T trichiura.
Introduction
Soil transmitted helminthiasis is caused by infections 
with the nematode worm Ascaris lumbricoides, the 
hookworms Necator americanus and Ancylostoma 
duodenale, and Trichuris trichiura. An estimated 5.3 
billion of people are at risk, while 1.5 billion are infected 
with at least one of the soil transmitted helminths.1 
Despite a global decline in infections, prevalence 
remains high in Asia, followed by sub-Saharan Africa 
and Latin America.1 A lumbricoides and T trichiura 
infections particularly affect preschool and school 
aged children, while hookworm infections are more 
prevalent in adults. Infected people predominantly live 
in poor conditions in the least developed countries, 
where households lack adequate facilities and clean 
water. Morbidity correlates with the number of 
worms harboured by infected individuals. While light 
infections commonly remain asymptomatic, moderate 
and heavy infections cause severe morbidity,2 
including growth stunting, intellectual impairment, 
cognitive and educational deficits, malnutrition, and 
iron deficiency anaemia.3 In 2015, the global burden 
of infections with soil transmitted helminths was 
estimated at 3.4 million disability adjusted life years 
(DALYs).4
The goal of the World Health Organization (WHO) 
is to reduce the prevalence of moderate and heavy 
infections with soil transmitted helminths in 
preschool and school aged children to below 1% by 
2020.5-7 To achieve this goal, school aged children 
in endemic areas are regularly treated in so called 
preventive chemotherapy programmes.5 6 8 In 2015, 
about 573 million children received preventive 
chemotherapy against soil transmitted helminths, 
corresponding to a global coverage of 59.5%.9 The 
ultimate target is to cover at least 75% of school 
aged children in need of treatment.6 Albendazole, 
mebendazole, levamisole, and pyrantel pamoate 
are currently on the WHO list of essential medicines 
for the treatment of such infections,6 7 while the two 
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WhAT IS AlReAdy knoWn on ThIS TopIC
The current strategy against soil transmitted helminths is preventive 
chemotherapy, mainly with albendazole, mebendazole, and, to a lesser extent, 
levamisole and pyrantel pamoate
A previous meta-analysis presented summary estimates of cure rates of these 
drugs based on a small number of randomised controlled trials
WhAT ThIS STudy AddS
The study provides up to date estimates of cure rates and egg reduction rates 
with network meta-analysis
The two most commonly used drugs have shortcoming in their efficacy profile: 
mebendazole has low efficacy against hookworm and albendazole and 
mebendazole show low performance against T trichiura
Efficacy albendazole and mebendazole against T trichiura has decreased over the 
past decades
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benzimidazoles—albendazole and mebendazole—
are the most widely used drugs in preventive 
chemotherapy programmes.8
The efficacy of albendazole, mebendazole, and 
pyrantel pamoate has been assessed in a systematic 
review for different dose regimens10 and by means of 
meta-analysis of randomised controlled trials for single 
doses.11 Albendazole, mebendazole, and pyrantel 
pamoate had high efficacy against A lumbricoides in 
terms of cure rates. Only albendazole was found to be 
efficacious in single dose regimen against hookworm 
(cure rate 72%). Both albendazole and mebendazole 
had unsatisfactory results against T trichiura at single 
doses with cure rates of 28% and 36%, respectively.11 
Of concern, recent results from randomised trials on 
Pemba Island (Tanzania) showed even lower cure rates 
for albendazole (2.6%) and mebendazole (11.8%) 
against T trichiura.12
We updated the findings from the two systematic 
reviews,10 11 including new evidence and applying 
network meta-analysis methods. The comparison of 
intervention effects among randomised controlled 
trials with conventional meta-analysis is limited by 
the constraint that only drugs tested in the same study 
can be compared.11 In contrast, network meta-analysis 
draws strength from direct and indirect comparisons 
through common comparators (such as placebo). 
Furthermore, multiple drugs can be compared and 
ranked.13-17 In addition, for the first time we meta-
analysed egg reduction rates, the standard key 
parameter for drug efficacy.18 Our analysis provides 
current evidence on anthelmintic drug efficacy, which 
is of considerable relevance to policy makers as they 
call for an adaptation of current treatment guidelines.
Methods
Search strategy and selection criteria
This review and meta-analysis is based on the 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) extension statement 
for network meta-analysis.19 The study protocol is 
provided in appendix 1. We conducted an electronic 
literature search on PubMed, ISI Web of Science, 
Embase, ScienceDirect, the Cochrane Central Register 
of Clinical trials, and the WHO library database. All 
studies from 1960 until 31 December 2016 were 
considered. The search was not restricted to any 
language, and, in case of non-English articles, native 
speakers were consulted for full text translations. The 
triple MeSH search terms included “albendazole”, 
“mebendazole”, “levamisole”, and “pyrantel 
pamoate” combined with either “trial”, “study”, or 
“case report” and “Ascaris lumbricoides”, “ascariasis”, 
“hookworm”, “Ancylostoma duodenale”, “Necator 
americanus”, “Trichuris trichiura”, “trichuriasis”, or 
“soil-transmitted helminths” (table A, appendix 1).
To be eligible for inclusion, studies had to be level 
1 randomised controlled trials (https://www.elsevier.
com/__data/promis_misc/Levels_of_Evidence.pdf) 
that reported the efficacy against A lumbricoides, 
hookworm, and T trichiura in terms of cure rates, egg 
reduction rates, or both. For this review we selected 
randomised controlled trials that included at least 
one treatment arm of the currently recommended7 10 20 
single dose regimens of albendazole (400 mg), 
mebendazole (500 mg), levamisole (80 mg or 2.5 mg/kg), 
or pyrantel pamoate (10 mg/kg). There were no age 
restrictions. Studies were excluded if they were not 
randomised controlled trials, used different drug 
regimens (such as multiple doses or different drug 
regimens), or combined different drugs or if the follow-
up was shorter than one or longer than six weeks.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
There are no plans to disseminate the results of the 
research to study participants or the relevant patient 
community. We did not evaluate whether the studies 
included in the review had any patient involvement.
Data extraction and assessment of risk bias
From each eligible randomised controlled trial we 
extracted number of infected participants at baseline, 
number of cured participants at follow-up, mean 
number of eggs at baseline, mean number of eggs 
at follow-up, percentage of egg reduction, measure 
of central tendency (arithmetic, geometric, or not 
described), information on the number of treatment 
arms, number of eligible treatment arms, year of 
publication, country, diagnostic method, age range, 
and time between treatment and follow-up.
Two independent reviewers (WM and JK) screened 
titles and abstracts for potential studies. When articles 
met the inclusion criteria, the entire manuscripts 
were scrutinised, and, for eligible trials, the data were 
extracted independently by the same reviewers. All 
included trials were assessed for quality by two different 
methods: that described by Jadad and colleagues,21 with 
scores ranging between 1 (lowest level) and 5 (highest 
level), and according to the Cochrane Collaboration 
Handbook (table A in appendix 2).22 The latter criteria 
assess studies for risk of bias in six different domains: 
random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, and 
selective reporting. Each domain is categorised into low, 
high, or unclear risk of bias. In case of discrepancies 
over extraction of data or scoring of the study quality, a 
third person (CS) was involved and the results discussed 
until consensus was reached.
Data synthesis and statistical analysis
The advantage of a network meta-analysis is the 
simultaneous combination of direct and indirect 
estimates of the treatment effect in one analysis. 
In data from clinical trials with direct estimates for 
drug A v B and other trials comparing A v C, we can 
estimate the relative treatment effect for B v C and 
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all three drugs can be ranked.13 23 To illustrate the 
network geometry, we have provided a separate plot 
for cure rates and egg reduction rates (fig 1).23 For 
the network meta-analysis of the cure rates, we used 
a method proposed by Kessels and colleagues.24 The 
method consists of rebuilding the original datasets 
based on sample sizes and case numbers retrieved 
from the publications. All datasets from studies with 
one, two, or more treatment arms were then pooled, 
and mixed logistic regression models were applied to 
the final pooled dataset. With this method even studies 
with only one eligible treatment arm can be included. 
The models included treatment as a fixed factor and 
random effects for studies and for treatment arms 
within studies. To mimic meta-regression analysis, we 
additionally included the respective regressor variable 
and its interactions with the treatments.
We recorded all egg reduction rates directly from the 
articles and used mixed linear models for the meta-
analysis of these rates. These models included the fixed 
factors treatment, infection intensity (dichotomised as 
above versus below median of baseline egg counts), 
measure of central tendency (arithmetic mean, 
geometric mean, or not described), and random effects 
for studies. We considered baseline infection intensity 
to increase precision and to achieve approximate 
normality of regression residuals.
Table 1 shows the average cure rates and egg 
reduction rates per treatment derived from the 
underlying regression models as marginal estimates. 
We presented one sided 95% confidence intervals if 
the limits of the respective two sided interval exceeded 
0 or 100%. We carried out one to one comparisons of 
cure rates and egg reduction rates by looking at the 
differences of the respective regression coefficients 
(fig 2). In the case of cure rates we used exponentiation 
to convert these differences into odds ratios. We also 
conducted a simple, pairwise meta-analysis of cure 
rates for the one to one comparison using the command 
metan in Stata. Table C in appendix 2 and fig B in 
Potential studies identied (n=301)
Randomised controlled trials met inclusion criteria for cure rates (n=56)
Randomised controlled trials met inclusion criteria for cure rates (n=55)
With data for A lumbricoides (n=44)
Albendazole (13)
Mebendazole (1)
Pyrantel pamoate (5)
Levamisole
Placebo
99
2
2 21
1 4
With data for hookworm (n=38) With data for T trichiura (n=38)
Reported no cure rates (n=1)
Excluded (n=245):
  Non-randomised (n=82)
  Not recommended dose (n=87)
  Follow-up too long (n=37)
  Drug only in combination (n=23)
  Data not extractable (n=16)
Reported no egg reduction rates (n=10)
Albendazole (12)
Mebendazole (1)
Pyrantel pamoate (3)
Levamisole
Placebo
138
5
2 12
1 3
Albendazole (13)
Mebendazole (1)
Pyrantel pamoate (2)
Levamisole
Placebo
89
2
2 21
1
1 1 1
2
Randomised controlled trials met inclusion criteria for egg reduction rates (n=46)
With data for A lumbricoides (n=33)
Albendazole (6)
Mebendazole (1)
Pyrantel pamoate (2)
Levamisole
Placebo
610
2
1
2
2
With data for hookworm (n=34) With data for T trichiura (n=33)
Albendazole (6)
Mebendazole (1)
Pyrantel pamoate (3)
Levamisole
Placebo
98
5
1 11
2
Albendazole (8)
Mebendazole (1)
Pyrantel pamoate (2)
Levamisole
Placebo
611
2
1 2
1 1 1
Fig 1 | Flowchart and network showing procedure for identification of relevant publications. Circular nodes show each treatment with circle size 
indicating amount of respective evidence and numbers in brackets indicating number of pooled studies with only one eligible treatment arm. Weight 
of line and number on line indicate number of direct treatment comparisons within same study
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appendix 3 show the respective summary odd ratios, 
I2, and τ2 statistics, where they are compared with the 
corresponding odd ratio estimates from network meta-
analysis.
In a second stage, we stratified analysis for cure rates 
and egg reduction rates according to continent, place 
of the study, sensitivity of diagnostic method, quality 
of the study, length of follow-up, intensity of infection 
at baseline, and year of publication (see tables D-J in 
appendix 2). By letting the treatment interact in the 
mixed regression model separately with study size and 
year, we estimated cure rates and egg reduction rates 
Table 1 | Average cure rates (%) and egg reduction rates (%) of albendazole, mebendazole, levamisole, and pyrantel pamoate against A lumbricoides, 
hookworm, and T trichiura based on network meta-analysis
Treatment
Cure rates Egg reduction rates
No of included 
studies
No of included 
participants Rate (95% CI)
No of included  
studies
No of included 
participants Rate (95% CI)
A lumbricoides
Placebo 14 842 12.7 (6.7 to 22.7) 9 525 20.7 (14.7 to 26.7)
Albendazole 34 3360 95.7*** (93.2 to 97.3) 26 2854 98.5*** (94.9 to 100.0)
Mebendazole 13 1548 96.2*** (92.3 to 98.1) 13 1529 98.0*** (94.0 to 100.0)
Levamisole 2 149 97.3*** (84.2 to 99.6) 1 125 96.4*** (82.3 to 100.0)
Pyrantel pamoate 11 1374 92.6*** (85.6 to 96.3) 6 284 94.3*** (88.3 to 100.0)
Total 44 7273 — 33 5137 —
Hookworm
Placebo 18 1309 15.2 (9.3 to 23.9) 14 1046 16.2 (5.3 to 27.1)
Albendazole 30 3104 79.5*** (71.5 to 85.6) 26 2839 89.6*** (81.9 to 97.3)
Mebendazole 14 2305 32.5* (20.8 to 46.9) 14 2263 61.0*** (52.0 to 69.9)
Levamisole 2 230 10.3 (2.4 to 35.2) 1 202 61.8* (30.3 to 93.3)
Pyrantel pamoate 7 230 49.8** (29.5 to 70.1) 5 144 71.9*** (54.7 to 89.0)
Total 38 7178 — 34 6494 —
T trichiura
Placebo 11 1417 8.6 (4.1 to 17.1) 28 1049 19.2 (6.9 to 31.4)
Albendazole 33 4432 30.7*** (21.0 to 42.5) 29 3407 49.9*** (39.0 to 60.6)
Mebendazole 13 2514 42.1*** (25.9 to 60.2) 14 2507 66.0*** (54.6 to 77.3)
Levamisole 2 203 29.5 (6.1 to 72.9) 1 197 28.3 (6.7 to 49.8)
Pyrantel pamoate 6 275 20.2 (7.3 to 44.7) 4 158 47.5** (25.5 to 69.6)
Total 38 8841 — 33 7318 —
* P<0.05, **P<0.01, ***P<0.001 for comparison with placebo.
A lumbricoides
  Albendazole v mebendazole
  Albendazole v levamisole
  Albendazole v pyrantel pamoate
  Mebendazole v levamisole
  Mebendazole v pyrantel pamoate
  Levamisole v pyrantel pamoate
Hookworm
  Albendazole v mebendazole
  Albendazole v levamisole
  Albendazole v pyrantel pamoate
  Mebendazole v levamisole
  Mebendazole v pyrantel pamoate
  Levamisole v pyrantel pamoate
T trichiura
  Albendazole v mebendazole
  Albendazole v levamisole
  Albendazole v pyrantel pamoate
  Mebendazole v levamisole
  Mebendazole v pyrantel pamoate
  Levamisole v pyrantel pamoate
1.1 (0.5 to 2.5)
1.6 (0.2 to 11.3)
0.6 (0.2 to 1.3)
1.4 (0.2 to 10.3)
0.5 (0.2 to 1.4)
0.3 (0.1 to 2.6)
0.1 (<0.1 to 0.3)***
<0.1 (<0.1 to 0.1)***
0.3 (0.1 to 0.7)**
0.2 (<0.1 to 1.1)
2.1 (0.7 to 6.0)
8.6 (1.5 to 50.0)*
1.6 (0.8 to 3.3)
0.9 (0.1 to 6.2)
0.6 (0.2 to 1.9)
0.6 (0.1 to 3.8)
0.3 (0.1 to 1.4)
0.6 (0.1 to 4.9)
0.01 1 60
Favours
	rst
treatment
Favours
second
treatment
Favours
	rst
treatment
Favours
second
treatment
Odds ratios for
cure rates (95% CI)
Odds ratios for
cure rates (95% CI)
-0.5 (-6.2 to 5.2)
-2.1 (-18.6 to 14.5)
-4.2 (-12.4 to 4.1)
-1.6 (-18.4 to 15.3)
-3.7 (-12.3 to 4.9)
-2.1 (-20.5 to 16.2)
-28.7 (-41.6 to -15.7)***
-27.9 (-66.8 to 11.0)
-17.8 (-39.7 to 4.1)
0.8 (-38.5 to 40.2)
10.9 (-11.8 to 33.6)
10.1 (-32.1 to 52.3)
16.1 (10.6 to 21.6)***
-21.6 (-40.3 to -2.9)*
-2.3 (-22.7 to 18.0)
-37.7 (-55.6 to -19.8)***
-18.4 (-40.1 to 3.2)
19.3 (-8.8 to 47.3)
-70 0 70
Dierence in egg
reduction rates (95% CI)
Dierence in egg
reduction rates (95% CI)
Fig 2 | Drug comparison based on network meta-analysis. Odds ratios for one to one comparisons of cure rates and difference for one to one 
comparisons of egg reduction rates are based on network meta-analysis for each drug and infection (*P<0.05, **P<0.01, ***P<0.001)
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for small (n=30) and large (n=300; table K in appendix 
2) studies and for years 1995 and 2015 (table L in 
appendix 2), to examine publication bias and evaluate 
the potential trends of efficacy over time.
We assessed the consistency between estimated 
odd ratios from direct and indirect comparisons by 
adding indicator variables for the two respective 
parallel treatments to the mixed logistic regression 
models. The difference of their regression coefficients 
was exponentiated to obtain the ratio between the 
odds ratio from direct and the odds ratio from indirect 
comparison (referred to as ratio of odds ratios). The two 
variables were obtained as the product of the respective 
treatment indicator variable and the indicator variable 
for studies that compared both treatments directly. The 
ratio of odds ratios (and 95% confidence intervals) 
measuring inconsistency between direct and indirect 
estimates are shown in appendix 3 (fig C). All analyses 
were done with STATA version 14.0 (StataCorp, College 
Station, TX, USA).
Results
Characteristics of included studies and bias 
assessment
We identified 301 potential studies of albendazole, 
mebendazole, levamisole, and pyrantel pamoate 
for treating soil transmitted helminth infections 
(fig 1). From these, we excluded 245: 82 were not 
randomised, 87 used a different dose regimen, 37 
had follow-up longer than six weeks, 23 used only 
drug combinations, and data were not extractable 
from 16 (table B in appendix 2). From the 56 
remaining studies, one included only egg reduction 
rates, while 10 did not report egg reduction rates. A 
total of 44 studies had data on cure rates against A 
lumbricoides, and 38 presented data on hookworm 
and T trichiura. For the analysis of egg reduction 
rates we included 34 studies for hookworm and 
33 for A lumbricoides and T trichiura. Studies 
including treatments consisting of placebo and 
albendazole and albendazole and mebendazole 
were most common. The inconsistency plot showed 
considerable differences between odd ratios of cure 
from direct and indirect comparisons for some of the 
drug pairs (fig C in appendix 3), but none of these 
differences reached significance.
The percentages of studies in the lowest categories 
for risk of bias were 41.1% for random sequence 
generation, 30.4% for allocation concealment, and 
51.8% for incomplete outcome data. The percentage 
of studies in the highest category for risk of bias was 
largest for blinding of participants and personnel 
(25.6%). The category of unclear risk was largest in all 
criteria other than “incomplete outcome data.” This 
was especially pronounced among studies published 
before the year 2000 (table M in appendix 2).
Drug efficacy against A lumbricoides
We evaluated 44 studies with an average Jadad score 
of 2.5 and a total of 7273 participants positive for A 
lumbricoides (table N in appendix 2 gives detailed 
numbers) to evaluate the effect of the four anthelmintic 
drugs against A lumbricoides (fig 1). Pooled estimates 
were based on 19 studies with only one treatment,25-43 
22 studies with two treatments,12 43-63 and three studies 
with three eligible treatments.64-66
The four anthelmintic drugs investigated showed 
highly significant superiority (all P<0.001) over 
placebo (the average cure rate with placebo was 
12.7% (95% confidence interval 6.7% to 22.7%; 
table 1). Estimated average cure rates were 95.7% 
(93.2% to 97.3%) for albendazole, 96.2% (92.3% 
to 98.1%) for mebendazole, 97.3% (84.2% to 
99.6%) for levamisole, and 92.6% (85.6% to 96.3%) 
for pyrantel pamoate. There were no significant 
differences among the four treatments in the one to 
one comparison (fig 2).
Thirty three studies reported egg reduction 
rates12 25 26 29 31 32 34-38 43-49 51 52 54-62 64 66 67 (fig 3). All 
treatment arms showed significantly higher rates 
(P<0.001) than placebo (20.7%, 95% confidence 
interval 14.7% to 26.7%; table 1), while there were no 
significant differences between the rates with the four 
treatments (fig 2). The highest estimated egg reduction 
rate (98.5%, 94.9% to 100.0%) was for albendazole, 
followed by 98.0% (94.0 to 100.0) for mebendazole, 
96.4% (82.3 to 100.0) for levamisole, and 94.3% (88.3 
to 100.0) for pyrantel pamoate.
Drug efficacy against hookworm
For estimating the drug efficacy against hookworm, we 
looked at data from 7178 individuals from 38 studies 
(table 1; table N in appendix 2) with an average Jadad 
score of 2.8. Pooled estimates included 12 studies with 
one treatment,25 26 30-32 34 36 38 42 43 68 21 studies with 
two treatments,12 43 44 46-58 62 63 68-70 and five studies 
with three treatments.64-66 71 72
The cure rate was 15.2% (95% confidence interval 
9.3% to 23.9%) for placebo (table 1). The rate 
with levamisole (10.3%, 2.4% to 35.2%) did not 
differ significantly from the placebo rate, but was 
significantly higher with albendazole (79.5%, 71.5% 
to 85.6%; P<0.001), mebendazole (32.5%, 20.8% 
to 46.9%; P=0.011), and pyrantel pamoate (49.8%, 
29.5% to 70.1%; P=0.001). The one to one comparison 
of cure rates showed a strongly increased odds of cure 
after the administration of albendazole compared 
with mebendazole (P<0.001), levamisole (P<0.001), 
and pyrantel pamoate (P=0.005, fig 2). The odds for 
levamisole were significantly lower than the odds for 
pyrantel pamoate (P=0.016).
We used data from 34 studies12 25 26 30-32 34 36 38 43 44 46-49 
51 52 54-58 62 64 66-72 (fig 3) to determine an egg reduction 
rate of 16.2% (95% confidence interval 5.3% to 27.1%) 
for placebo, which was significantly lower than the 
rates for all active treatments (table 1). Albendazole 
had the highest average rate of 89.6% (81.9% to 
97.3%), followed by pyrantel pamoate (71.9%, 54.7% 
to 89.0%), levamisole (61.8%, 30.3% to 93.3%), and 
mebendazole (61.0%, 52.0% to 69.9%). The one to one 
comparison showed a significant difference between 
albendazole and mebendazole (P<0.001, fig 2).
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Drug efficacy against T trichiura
We used data from 38 studies (average Jadad score 
of 2.6), including 8841 participants positive for T 
trichiura (table 1; table N in appendix 2) for analysis 
of cure rates of the four drugs against T trichiura. 
Pooled estimates were based on 16 trials with one 
treatment,25 26 29-33 35-38 40 42 43 73 74 19 studies including 
two treatments,12 43 44 46-51 53-59 62 63 75 and three studies 
with three treatments.64-66
The cure rate was 8.6% (95% confidence interval 
4.1% to 17.1%) with placebo, which was not 
significantly different from the rates with levamisole 
(29.5%, 6.1% to 72.9%) and pyrantel pamoate 
(20.2%, 7.3% to 44.7%; table 1). Albendazole and 
mebendazole showed significantly higher efficacy 
than placebo, with estimated cure rates of 30.7% 
(21.0% to 42.5%; P<0.001) and 42.1% (25.9% to 
60.2%; P<0.001), respectively. We found no significant 
differences among the rates of the four treatments 
comparing them one to one (fig 2).
We used 33 studies for analysis of the egg reduction 
rates12 25 26 29 31 35-38 43 44 46-49 51 54 55-58 62-64 66 67 73-76 
(fig 3). The average rate was 19.2% (95% confidence 
interval 6.9% to 31.4%) for placebo, which was 
significantly lower than the rates for albendazole 
(P<0.002), mebendazole (P<0.001), and pyrantel 
pamoate (P=0.008) but comparable with the rate 
for levamisole (28.3%, 6.7% to 49.8%; table  1). The 
highest rate of 66.0% (54.6% to 77.3%) was estimated 
for mebendazole, which was significantly higher than 
the rate for albendazole (49.9%, 39.0% to 60.6%; 
P<0.001) and levamisole in the one to one comparison 
(fig 2). For pyrantel pamoate the rate was 47.5% 
(25.5% to 69.6%).
Stratification by publication year (before v after 
2000), resulted in a significantly reduced cure rate for 
albendazole (44.9% (95% confidence interval 29.4% 
to 61.5%) v 23.7% (14.2% to 36.7%); P=0.039; 
table J in appendix 2). The interaction analysis, with 
estimates for 1995 and 2015, showed a significant 
decrease in cure rates for albendazole from 38.6% 
(26.2% to 52.7%) to 16.4% (7.7% to 31.3%; P=0.027) 
and in egg reduction rates for albendazole from 
72.6% (53.7% to 91.5%) to 43.4% (23.5% to 63.3%; 
P=0.049) and mebendazole from 91.4% (72.9% to 
100.0%) to 54.7% (34.6% to 74.8%; P=0.014; table 
L in appendix 2).
discussion
Summary of key findings
Albendazole, the most widely used anthelmintic drug 
against A lumbricoides and hookworm, is highly 
effective, both in terms of cure rates and egg reduction 
rates. With about 134 million doses distributed in 
2015, mebendazole is the second most widely used 
drug for infections with soil transmitted helminths.77 
It has high efficacy against A lumbricoides and low 
activity against hookworm. Levamisole and pyrantel 
pamoate have high efficacy against A lumbricoides, 
and pyrantel pamoate has moderate efficacy against 
hookworm. The weakness of the currently available 
drugs is their low efficacy against T trichiura, for 
which mebendazole showed the best performance. 
This finding emphasises the urgent need for new drugs 
with higher efficacy against T trichiura for preventive 
chemotherapy programmes.10 11
Our review provides up to date evidence on the 
efficacy of the four recommended anthelmintic 
drugs—albendazole, mebendazole, and the less widely 
used levamisole and pyrantel pamoate—based on a 
thorough review of the literature. For the first time a 
network-meta analysis was applied, and we meta-
analysed summary estimates on egg reduction rates, a 
key parameter for efficacy of anthelmintic drugs.18
Strength and limitations
The main strength of our study was the innovative 
data analysis including the two measures of efficacy 
of anthelmintic drugs: cure rates and egg reduction 
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Fig 3 | Egg reduction rates for albendazole, mebendazole, 
levamisole, and pyrantel pamoate. Median, third quarter 
(white bar), second quarter (shaded bar), and individual 
study specific rates (solid circles) for each drug against 
A lumbricoides, hookworm, and T trichiura. Negative 
values of rates were set to zero in this figure
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rates. By applying a network meta-analysis, we could 
increase the evidence by including the efficacy results 
of a higher number of randomised controlled trials than 
in a previous meta-analysis.11 Furthermore, the model 
from Kessels and colleagues24 allowed the inclusion of 
studies with only one eligible treatment arm. To assess 
consistency of estimates, we compared odd ratios 
of cure from direct and indirect comparisons of the 
treatments with a plot (fig C in appendix 3). Although 
some of the differences were quite large, potentially 
challenging the validity of the indirect comparisons, 
none of the differences reached significance.
The reviewed randomised controlled trials cover 
the past 50 years of research. This inevitably leads 
to huge qualitative differences among the studies, 
which reflects the main challenge and limitation of 
our analyses. There were major disparities among 
the included studies, which affect drug efficacy—for 
instance, diagnostic method, infection intensity at 
baseline, statistical analyses, and sample size.
The diagnostic methods used in the reviewed 
studies ranged from lowest sensitivity methods, such 
as the direct smear, up to multiple Kato-Katz thick 
smears, which have a reasonable sensitivity. The 
sensitivity of diagnostic methods is associated with 
the infection intensity at baseline—for example, Kato-
Katz has a reduced sensitivity for low egg counts.78 
Both the diagnostic method and infection intensity 
at baseline directly influence cure rates and egg 
reduction rates.79-81 While the results stratified by 
infection intensities did not show a clear tendency for 
efficacy in this review, the sensitivity of the diagnostic 
method had an impact. Stratification of efficacy by 
low and moderate sensitivity of the diagnostic method 
significantly decreased cure rates of albendazole 
against A lumbricoides (P=0.044) and hookworm 
(P=0.023). We cannot, however, explain the increase 
in egg reduction rates with albendazole (P=0.024) 
against T trichiura (table E in appendix 2).
An additional limitation of the diagnostic methods 
(Kato-Katz, McMaster, etc) is their inability to 
distinguish between A duodenale and N americanus. 
Few included studies reported efficacies for specific 
hookworm species. The overall efficacies might 
differ according to the species. For example, while 
both hookworm species are somewhat susceptible to 
pyrantel pamoate, N americanus is reported to be less 
sensitive.82 The commonly higher abundance of N 
americanus in Africa than in Asia83 might have led to 
the borderline significant difference (P=0.053) in cure 
rates of pyrantel pamoate in Asia (64%) and Africa 
(27%; table C in appendix 2).
The network meta-analysis for egg reduction rates 
was limited by the lack of precision estimates in 
most of the studies and by the different choices of the 
measure of central tendency (arithmetic or geometric 
mean). There is an ongoing debate about advantages 
and disadvantages of the two systematically different 
means, while WHO now recommends the arithmetic 
mean.18 84 A few, mainly older, studies did not even 
report which measure of central tendency they used. 
In the absence of standard errors and confidence 
intervals, we could not optimise the precision of 
meta-analytic estimates. Moreover, as arithmetic and 
geometric means are systematically different, we had 
to adjust analyses of egg reduction rates for the type 
of mean.
To deal with potential publication bias, we compared 
results of smaller and larger studies in an interaction 
analysis. We might have slightly overestimated the 
effect of albendazole against hookworm, where the 
cure rate showed an almost significant negative 
association with study size (P=0.053). While the cure 
rates of A lumbricoides showed positive or stable 
associations with study size for all treatments, the 
rates of T trichiura after treatment with albendazole 
and mebendazole slightly decreased with increasing 
study size, yet not significantly. Thus, we did not 
find consistent evidence of publication bias (table 
J in appendix 2). The small number of available and 
eligible studies for levamisole is another limitation 
of our work. Consequently, all estimates relating to 
levamisole (cure rates, egg reduction rates, and odd 
ratios) have wide confidence intervals. Nonetheless, 
we present the first pooled estimates of efficacy for 
levamisole against hookworm, showing a low average 
cure rate (10.3%, with an upper 95% confidence limit 
of 35.2%), which conflicts with the fact that the drug is 
recommended for the treatment.3 11
Clinical implications
Efficacy of anthelmintic drugs is defined by cure rates 
and egg reduction rates. As both parameters have to be 
taken into consideration in comparisons of the efficacy 
of the drugs for each helminth species, the comparison 
was done qualitatively. Against A lumbricoides we 
found no significant differences, and all drugs had 
high efficacy. Albendazole had the highest efficacy for 
treating hookworm infections with significantly higher 
cure rates, followed by pyrantel pamoate, and lowest 
efficacy for levamisole and mebendazole when used at 
single oral doses. With regard to T trichiura infections, 
mebendazole had the highest, yet only moderate, 
efficacy, with significantly higher egg reduction rates 
than albendazole. The cure rates of levamisole and 
pyrantel pamoate did not differ from placebo.
Moreover, after stratification by year, we found 
a significant decrease in cure rates for albendazole 
against T trichiura (P=0.039) and a remarkable 
reduction against hookworm (table I in appendix 
2). These results were even more pronounced in the 
interaction analysis. The cure rates for albendazole 
against T trichiura remained significantly lower 
(P=0.027). Furthermore, egg reduction rates of 
albendazole (p=0.027) against hookworm and of 
albendazole (P=0.049) and mebendazole (P=0.014) 
against T trichiura (table K in appendix 2) significantly 
decreased over time, which might be attributable to 
drug resistance.85 Several studies correlated reduced 
efficacies of benzimidazoles58 64 70-72 86 with emerging 
resistance. In 2015, more than a billion people infected 
with lymphatic filariasis and soil transmitted helminths 
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were treated with albendazole,9 which is causing high 
drug pressure on parasites and might trigger drug 
resistance. In veterinary medicine, frequently repeated 
treatment with benzimidazoles has caused resistance 
in numerous nematode species.84 87 88 Resistance to 
anthelmintic drugs in humans, however, has not yet 
been shown. While the reduction in efficacy could 
be explained by emerging resistance, other factors, 
related to drug regimen, diagnostics, or host and 
parasite characteristics, might have contributed to 
the reduction.18 We evaluated the impact of some 
potential confounders but did not assess the influence 
of, for example, drug quality (original versus generic 
drugs), change in compliance over the years, or the 
day to day variation in egg excretion.18 89 Hence, 
future randomised controlled trials should follow 
a harmonised design to reduce confounders, as 
suggested by WHO,18 which will yield improved 
summary estimates of efficacy of anthelmintic drugs.
Conclusion
Our data confirm that the most widely used drugs—
albendazole and mebendazole—have shortcomings in 
their efficacy profile, especially against infections with 
hookworm and T trichiura. Alarmingly, the efficacy of 
albendazole and mebendazole has decreased over time. 
As the two most widely distributed drugs in preventive 
chemotherapy—albendazole and mebendazole—have 
been in use for almost 50 years, the threat of resistance 
is real and immediate. For careful monitoring of 
potential resistance, our summary estimates might 
help to revise current reference figures of efficacy.18
There is an imminent need to strengthen 
efforts to develop new drugs for soil transmitted 
helminths. Alternatively, old and new drugs—such 
as tribendimidine, oxantel pamoate, moxidectin, or 
ivermectin—with different efficacy profiles could be 
used in combination with the recommended drugs 
to successfully tackle infections with all three soil 
transmitted helminths.12 90 Only with an integrated 
approach combining improved sanitation, health 
education,91-93 and scaling up of research for new 
anthelmintic drugs and use of drug combinations 
for preventive chemotherapy will we achieve the 
ultimate goal to control soil transmitted helminth 
infections. Furthermore, future randomised controlled 
trials should follow a harmonised design to reduce 
confounders and yield improved summary estimates 
of efficacy of anthelmintic drugs.
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